PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS
申请人:Burger Matthew
公开号:US20100249126A1
公开(公告)日:2010-09-30
Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS
申请人:BURGER Matthew
公开号:US20120225859A1
公开(公告)日:2012-09-06
Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
Pyrimidine derivatives used as pi-3 kinase inhibitors
申请人:Novartis AG
公开号:EP2261223A1
公开(公告)日:2010-12-15
Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.